摘要
目的探讨瑞舒伐他汀对早发冠心病患者血管内皮功能及血小板指标的影响。方法选取2015年2月至2016年2月期间于攀枝花市攀钢集团总医院进行诊治的54例早发冠心病患者为研究对象,将其根据随机数字表法分为对照组和观察组,每组27例,对照组患者进行常规治疗,观察组在对照组基础上加用瑞舒伐他汀治疗,然后将两组患者治疗前和治疗后1个月、3个月与6个月时的血管内皮功能相关指标及血小板指标进行比较。结果治疗前两组患者的血管内皮功能相关指标及血小板指标比较差异均无统计学意义(P>0.05),而治疗后1个月、3个月及6个月,两组患者的血管内皮功能相关指标及血小板指标均持续改善,治疗后6个月,观察组患者的内皮素1(ET-1)、一氧化氮(NO)、血管性血友病因子(vWF)、可溶性血管间粘附分子1(sVCAM-1)、血流介导的内皮舒张功能(FMD)、内皮依赖性舒张反应(EDD)及非内皮依赖性舒张功能(EID)及平均血小板体积(MPV)、血小板分布宽度(PDW)及膜表面α-颗粒膜蛋白-140(GMP-140)均明显优于对照组,差异均有统计学意义(P<0.05)。结论瑞舒伐他汀可显著改善早发冠心病患者的血管内皮功能及血小板指标,改善患者的循环状态。
Objective To explore the influence of rosuvastatin on vascular endothelial function and platelet indexes in patients with premature coronary heart disease. Methods A to tal of 54 patients with premature coronary heart disease treated in our hospital from February 2015 to February 2016 were enrolled. They were divided into observation group and control group by a rand om number table（27 cases in each group）. The control group was treated with routine treatment, and the observation group was treated with control-based therapy and rosuvastatin. The vascular endothelial function and platelet indexes of two groups were investigated before the treatment and at the first, third and sixth month after the treatment. Results No statistically significant difference was observed between two groups on the change of vascular endothelial function and platelet indexes before the treatment（P〈0.05）, while these indexes of two groups at first, third and sixth month after the treatment were all continuously improved. At the sixth month after treatment, vascular endothelial function related indexes endothelin-1（ET-1）, nitric oxide（NO）, von Willebrand factor（vWF）, soluble vascular adhesion molecule 1（sVCAM-1）, flow-mediated dilation fmd（FMD）, endothelial-dependent vasodilation（EDD） and endothelium-independent dilation（EID） and platelet indexes meam platelet volume（MPV）, platelet distribution width（PDW） and platelet α-granule membrane protein 140（GMP-140） of observation group at sixth month after the treatment were respectively significantly better than those of control group（P〈0.05）. Conclusion The rosuvastatin can significantly improve the vascular endothelial function and platelet indexes of patients with premature coronary heart disease, so it can improve the circulation state of patients.
出处
《海南医学》
CAS
2017年第15期2431-2434,共4页
Hainan Medical Journal
基金
四川省攀枝花市科技支撑计划(编号:2016013026)
关键词
瑞舒伐他汀
早发冠心病
血管内皮功能
血小板
Rosuvastatin
Premature coronary heart disease
Vascular endothelial function
Platelet
